SHEEL BIOTECH LIMITED
An ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 Certified Company
CIN-U24239DL1991PLC046531 ESTD. 1991
Tissue Culture, Organic Farming, Planting & Landscaping, FPO, Hortiprojects, Berry Cultivation
Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

To,
The Manager,
Listing Compliance Department
National Stock Exchange of India Limited
Exchange Plaza, Bandra Kurla Complex,
Bandra (East), Mumbai-400051

Date:- 13th November 2026

SYMBOL: SHEEL
ISIN- INE0YJV01017

Subject: Outcome of Board Meeting dated November 14, 2025

Ref: Regulation 30 and Schedule III of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, (hereinafter referred "SEBI LODR")

Dear Sir/Madam,

Pursuant to Regulation 30 and Schedule III of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform that the Board of Directors of the Company in their Board Meeting held on today i.e. Saturday, November 15, 2025, commenced at 11:00 AM and concluded at 04:00 P.M, has inter alia, considered and approved the following agendas items:

1. the Unaudited Financial Results for the Half Year ended September 30, 2026 along with the Limited Review Report thereon:
Pursuant to Regulation 33 of the SEBI LODR, kindly find the enclosed herewith as Annexure-A the following:

i) Limited Review Report issued by the Statutory Auditor of the Company on the aforesaid Financial Results.
ii) A copy of the Unaudited Standalone Financial Results for the half year ended September 30, 2026.

The above may be accessed on the Company's website at https://sheelbiotech.com
You are requested to kindly take the same on record.

Thanking you.

For and on Behalf of Sheel Biotech Limited

Anupam Pandey
Company secretary and compliance officer
Membership No- 60975

S S MANGLA & CO LLP
Chartered Accountants

SCO 201 SHOPPING CENTER,
Faridabad, SECTOR-8, FARIDABAD
121006 rajatmangla@ssmangla.co.in
9811110459

Limited Review Report

To
The Board of Directors,
M/s Sheel Biotech Limited
8, Balaji Estate, 2nd Floor, Block C, Guru Ravidas Marg, Kalkaji
South Delhi, Delhi, India, 110019

Independent Auditor's Review Report on the Half yearly Unaudited standalone Financial Result of the Company pursuant to the Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended

1. We have reviewed the accompanying Statement of Unaudited Financial Results of Sheel Biotech Limited ("the Company") for the half year ended September 30, 2026, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended (the "Listing Regulations").

2. This Statement which is the responsibility of the Company's Management and approved by the Company's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in the Accounting Standard 25 "Interim Financial Reporting" ("AS 25"), prescribed under Section 133 of the Companies Act, 2013 ("the Act") read with relevant rules issued thereunder and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on these statements based on our review.

3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India (ICAI). This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review of interim financial information consists of making inquiries, primarily of the Company's personnel responsible for financial and accounting matters and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing specified under section 143(10) of the Companies Act, 2013 and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

S MANGLA & CO. LLP
CHARTERED ACCOUNTANTS
FARIDABAD

4. Based on our review conducted as stated in paragraph 3 above, nothing has come to our attention, that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in the aforesaid Accounting Standard and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed including the manner in which it is to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

S S MANGLA & CO. LLP
CHARTERED ACCOUNTANTS
FARIDABAD

For S S MANGLA & CO LLP
Chartered Accountants
FRN: 0N500055

SHYAM SUNDER MANGLA
(PARTNER)
Membership No. 088290

Place:- Delhi
Date: 13-11-2026
UDIN:26088290MRFFJX4992

SHEEL BIOTECH LIMITED

An ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 Certified Company
CIN-U24239DL1991PLC046531 ESTD. 1991

Tissue Culture, Organic Farming, Planting & Landscaping, FPO, Hortiprojects, Berry Cultivation
Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

Unaudited Balance Sheet as at 30.09.2026

(Amount in Rs. Lakhs)

Particulars	Half Year Ended April 2026 to Sept 2026 Unaudited	Half Year Ended April 2025 to Sept 2025 Unaudited	Year Ended April 2025 to March 2026 Audited
EQUITY AND LIABILITIES			
Shareholder'S Funds			
Share Capital	2,035.26	1,495.26	2,035.26
Reserves And Surplus	11,002.42	6,910.86	10,663.91
Non-Current Liabilities			
Long-Term Borrowings	528.38	785.59	124.38
Deferred Tax Liabilities (Net)	0.00	0.00	0.00
Other Long term Liabilities	0.00	0.00	0.00
Long-Term Provisions	68.18	64.64	57.60
Current Liabilities			
Short-Term Borrowings	1,450.87	1,920.33	773.53
Trade Payable			
(i) total outstanding dues of micro enterprises and small	5.31	4.15	0.27
(ii) total outstanding dues of creditors other than	248.59	373.72	305.74
Other Current Liabilities	1,534.69	621.73	597.96
Short-Term Provisions	105.44	213.80	19.78
Total	**16,979.13**	**12,390.08**	**14,578.43**
Assets			
Non-Current Assets			
Property, Plant and Equipment & Intangible Assets			
(I) Property, Plant and Equipment	1,405.48	699.50	946.63
(ii) Intangible assets	1.04	1.26	1.15
(iii) Capital work-in-progress	542.44	0.00	345.40
Non- Current Investment	79.20	79.20	79.20
Deferred Tax Assets (Net)	15.03	1.42	10.46
Long Term Loans And Advances	0.00	0.00	0.00
Other Non-Current Assets	340.56	522.11	412.85
Current Assets			
Trade Receivables	6,628.81	5,145.32	6,180.50
Cash And Cash Equivalents	21.06	20.47	218.29
Inventory	3,168.20	4,204.98	2,956.51
Short Term Loans And Advances	1,095.76	475.08	296.10
Other Current Assets	3,681.55	1,240.74	3,131.34
Total	**16,979.13**	**12,390.08**	**14,578.43**
Significant Accounting Policies & Notes on Accounts			

Notes:

1. The above standalone financial results of the company were reviewed and recommended by the Audit Committee and subsequently approved by the Board of Directors at its meeting held on 13th November 2026. The Statutory Auditors have carried out their limited review of the financial result for the half year ended on September 30, 2026.

2. The figures for the half year ended March 31, 2026 are the balancing figures between audited figures of full financial year and interim unaudited period to date figures upto six month ended 30th September, 2025.

3. These financial results have been prepared in accordance with the recognition and measurement principles laid down in the AS 25 'Interim Financial Reporting prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles relevant thereto.

4. The comparative financial information for the half year ended September 30, 2025 has been presented based on the management-certified financial statements and has not been subjected to any audit or review.

5. The company operates in a single segment ie Agriculture, hence segment reporting is not applicable.

6. As on date of the 30-09-2026 no investor complaints were not there.

7. Previous period figures have been regrouped / reclassified where required to make them compatible with the figures of current period.

8. The Equity shares of the company are listed on NSE (SME Platform) Stock Exchange as referred in Chapter XB of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2009 and hence exempted from compulsory adoption of IND AS for preparation of Financial Statement vide Notification dated February 16, 2015 issued by Ministry of Corporate Affairs

For & on behalf of the board of Sheel Biotech Limited



Divye Chandak
Managing Director
DIN :- 07100902

SHEEL BIOTECH LIMITED

An ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 Certified Company
CIN-U24239DL1991PLC046531 ESTD. 1991

Tissue Culture, Organic Farming, Planting & Landscaping, FPO, Hortiprojects, Berry Cultivation
Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

Statement of Standalone Unaudited Statement Profit & Loss for the Half year ended 30.09.2026

(Amount in Rs. Lakhs except EPS)

Particulars	Half Year Ended April 2026 to Sept 2026 Unaudited	Half Year Ended April 2025 to Sept 2025 Unaudited	Half Year Ended October 2025 to March 2026 Unaudited	Year Ended April 2025 to March 2026 Audited
Income:				
I. Revenue From Operations	5,055.63	2,184.91	8,817.33	11,002.24
II. Other Income	32.59	14.63	56.64	71.27
III. Total Income (I +II)	**5,088.22**	**2,199.54**	**8,873.97**	**11,073.51**
IV. Expenses:				
Cost of Material Consumed	3,328.76	1,240.57	5,554.44	6,795.01
Purchase of Stock-in-Trade	-	-	0.00	-
Changes in inventories of finished goods, work-inprogress and Stock-in-Trade	-	(266.45)	266.45	-
Employee Benefit Expense	819.93	691.56	781.10	1,472.66
Finance Costs	127.94	114.88	76.57	191.45
Depreciation And Amortization Expense	49.18	51.30	55.28	106.58
Other Expenses	349.77	342.57	763.65	1,106.22
IV. Total Expenses	**4,675.59**	**2,174.43**	**7,497.49**	**9,671.92**
V. Profit Before Exceptional And Extraordinary Items And Tax (III - IV)	412.63	25.11	1,376.48	1,401.59
VI. Exceptional Items	0.00	0.00	0.00	0.00
VII. Profit Before Extraordinary Items And Tax (V - VI)	412.63	25.11	1,376.48	1,401.59
VIII. Extraordinary Items	0.00	0.00	0.00	0.00
IX. Profit Before Tax (VII- VIII)	**412.63**	**25.11**	**1,376.48**	**1,401.59**
X. Tax Expense:				
(1) Current Tax	78.65	0.94	242.43	243.37
(2) Deferred Tax	-4.56	5.32	(9.05)	(3.73)
(3) Taxation For Earlier Years	0.00	0.00	(13.68)	(13.68)
XI. Profit (Loss) For The Period From Continuing Operations	338.54	18.85	1,156.78	1,175.64
XII. Profit/(Loss) From Discontinuing Operations	0.00	0.00	0.00	0.00
XIII. Tax Expense Of Discontinuing Operations	0.00	0.00	0.00	0.00
XIV. Profit/(Loss) From Discontinuing Operations (After Tax)	0.00	0.00	0.00	0.00
XV. Profit (Loss) For The Period	338.54	18.85	1,156.78	1,175.64
XVI. Earning Per Equity Share:				
(1) Basic	1.66	0.13	6.56	6.69
(2) Diluted	1.66	0.13	6.56	6.69
Significant Accounting Policies & Notes on Accounts				

For & on behalf of the board of Sheel Biotech Limited

SHEEL BIOTECH LTD.

Divye Chandak
Managing Director
DIN :- 07100902

SHEEL BIOTECH LIMITED

An ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 Certified Company
CIN-U24239DL1991PLC046531 ESTD. 1991

Tissue Culture, Organic Farming, Planting & Landscaping, FPO, Hortiprojects, Berry Cultivation
Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

Unaudited Statement of Cash Flows for the half year ended 30.09.2026

(Amount in Rs. Lakhs)

	Particulars	Half Year Ended April 2026 to Sept 2026 Unaudited	Half Year Ended April 2025 to Sept 2025 Unaudited	Year Ended April 2025 to March 2026 Audited
A	**Cash Flow From Operating Activities**			
	Net Profit Before Tax	412.63	25.11	1,401.59
	Adjustments For			
	Depreciation	49.18	51.30	106.58
	Finance Cost	127.94	114.88	191.45
	Interest Income	(5.47)	(6.01)	(25.34)
	Gain on foreign exchange	(2.57)	-	0.00
	Profit on Sale of Fixed Assets	0.00	0.00	0.00
	Profit on Sale of Shares	0.00	0.00	0.00
	Loss on Sale of property Plant and Equipment	0.00	0.00	4.53
	Operating Profit Before Working Capital Changes	581.71	185.28	1,678.82
	Adjustments For			
	(Increase) / Decrease In Trade Receivables	(448.31)	362.59	(672.59)
	(Increase) /Decrease In Other Current Assets	(550.22)	(1,123.14)	(2,853.19)
	(Increase) /Decrease In Other Non-Current Assets	0.00	0.00	0.00
	Increase / (Decrease) In Other Long Term Liabilities	0.00	0.00	0.00
	Increase / (Decrease) In Trade Payables	(52.11)	(36.22)	0.00
	Increase/ (Decrease) In Other Current Liabilities	936.72	103.36	0.00
	Increase/ (Decrease) In Long Term Provisions	10.58	0.00	0.00
	Increase/ (Decrease) In Short Term Provisions	85.66	(1.51)	0.00
	Increase/ (Decrease) In Long Term Borrowings	0.00		
	Increase/ (Decrease) In Short Term Borrowings	0.00	0.00	(480.34)
	Increase/ (Decrease) In Trade & Other Payables	0.00	0.00	(30.24)
	(Increase) /Decrease In Short term loans and advances	(799.66)	0.00	(151.69)
	(Increase) / Decrease In Inventories	(211.69)	(266.45)	982.02
	(Increase) / Decrease In Deferred Tax Assets	-		
	Cash Generated From Operations	(447.31)	(776.09)	(1,527.21)
	Less: Taxes Paid / (Refund) - Net	78.65	0.94	(229.68)
	Net Cash Inflow / (Outflow) From Operating Activities	(526.00)	(777.03)	(1,756.89)
B	**Cash Flow From Investing Activities**			
	Sale Of Fixed Assets	0.00	0.00	10.50
	(Purchase) Of Fixed Assets	(704.96)	(3.24)	(665.95)
	(Increase) / Decrease In Short Term Loans & Advances	-	23.67	0.00
	(Increase) / Decrease In Long Term Loans & Advances	-	(135.92)	0.00
	(Increase) / Decrease In Non- Current Investment	-	0.00	0.00
	(Increase) / Decrease In Current Investment	-	0.00	0.00
	(Increase) / Decrease In Non - Current Assets	72.29	-	(26.66)
	Interest Income and profit on sale of Asset	5.47	6.01	25.34
	Net Cash Flows From Investing Activities	(627.20)	(109.48)	(656.77)

SHEEL BIOTECH LIMITED
An ISO 9001:2015, ISO 14001:2015 and ISO 45001:2018 Certified Company
CIN-U24239DL1991PLC046531 ESTD. 1991
Tissue Culture, Organic Farming, Planting & Landscaping, FPO, Hortiprojects, Berry Cultivation
Registered Office - 8 Balaji Estate, Tower C, 2nd Floor, Guru Ravidas Marg, Kalkaji, New Delhi, India - 110019
Phone : +91 8882260863, E-mail : info@sheelbiotech.com, Website : www.sheelbiotech.com

C	**Cash Flow From Financing Activities**			
	Dividends Paid	-	-	0.00
	Increase / (Decrease) In Other Long Term Liabilities	-	5.67	(1.37)
	Increase/ (Decrease) In Long-Term Borrowings	404.00	303.33	(357.87)
	Increase/ (Decrease) In Short-Term Borrowings	677.34	666.46	-
	Issue of Shares For Cash	-	-	3,561.50
	Share Issue Expenses	-	-	(425.25)
	Finance Costs Paid	(127.94)	(114.88)	(191.45)
	Gain on foreign exchange	2.57	-	-
	Net Cash Flows From Financing Activities	955.97	860.58	2,585.55
D	**Net Changes In Cash & Cash Equivalents (A+B+C)**	(197.24)	(25.93)	171.89
	Cash & Cash Equivalents At The Beginning Of The Year	218.29	46.40	46.40
	Cash & Cash Equivalents At The End Of The Year	**21.06**	**20.47**	**218.29**
	Components Of Cash And Cash Equivalents			
	Balances with banks	2.31	3.75	198.98
	Cash on hand	18.75	16.72	19.30
	Fixed deposits	0.00	0.00	0.00
	Total of Cash & Cash Equivalents :	21.06	20.47	218.28

Notes :-

01. The above Cash Flow Statements has been prepared in accordance with the 'Indirect Method' as set out in the Accounting Standard 3 on Cash Flow Statements issued by the Institute of Chartered Accountants

For & on behalf of the board of Sheel Biotech Limited

Divye Chandak
Managing Director
DIN :- 07100902